Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
...Biotech Annual Meeting - Tides, Las Vegas, USA - BIO, Vancouver, USA - microRNA Symposium 2009, Vienna. - DDD Meeting Japan - smi 4th conference on RNAi, miRNA and siRNA - XV International Symposium on Atherosclerosis - 4th Nucleic Acid Chemical Biology (NACB) Symposium...GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
...s for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index smi (Swiss Market Index SMI(R)) GeneraMedix, Inc. GeneraMedix Inc. is a privately held pharmaceutical company specializing in difficult to ...Cell Therapeutics Receives Additional NASDAQ Notification
...nc. ("SMI") and issued additional common shares to smi shareholders. Marketplace Rule 4350(i)(1)(C) req...d to provide that the Company shall pay accredited smi stockholders an immediate substitute "earn-out" pa...ny issued 38,186,911 shares of its common stock to smi stockholders, which is in excess of 20% of the Com...Starch Medical Launches New, Bioinert Surgical Hemostats
...led with custom delivery systems, have been favorably received in a diverse range of surgical applications in Europe, Asia and Latin America." smi is a privately-held medical device company engaged in the design, manufacture, marketing and licensing of breakthrough, hemostatic solutions. Starch M...